Compare TORO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TORO | CRBP |
|---|---|---|
| Founded | 2022 | 2009 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 190.3M |
| IPO Year | 2022 | 2014 |
| Metric | TORO | CRBP |
|---|---|---|
| Price | $6.42 | $8.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 19.9K | ★ 577.7K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $2.81 | $7.12 |
| 52 Week High | $8.50 | $20.56 |
| Indicator | TORO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 36.08 |
| Support Level | $4.87 | $7.62 |
| Resistance Level | $6.49 | $9.66 |
| Average True Range (ATR) | 0.28 | 0.70 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 88.81 | 5.66 |
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.